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Abstract
DIVA (differentiating infected from vaccinated animals) vaccines have proven extremely useful
for control and eradication of infectious diseases in livestock. We describe here the
characterization of a serologic marker epitope, so-called epitope-M201, which can be a potential
target for development of a live-attenuated DIVA vaccine against porcine reproductive and
respiratory syndrome virus (PRRSV). Epitope-M201 is located at the carboxyl terminus (residues
161-174) of the viral M protein. The epitope is highly immunodominant and well-conserved
among type-II PRRSV isolates. Rabbit polyclonal antibodies prepared against this epitope are
non-neutralizing; thus, the epitope does not seem to contribute to the protective immunity against
PRRSV infection. Importantly, the immunogenicity of epitope-M201 can be disrupted through the
introduction of a single amino acid mutation which does not adversely affect the viral replication.
All together, our results provide an important starting point for the development of a live-
attenuated DIVA vaccine against type-II PRRSV.
Keywords
PRRSV; M protein; Serological marker epitope; DIVA vaccines
1. Introduction
Porcine reproductive and respiratory syndrome (PRRS) was first reported in the U.S. in late
1980s [1]. Since then, the disease has been widespread in most swine-producing countries
worldwide, causing substantial economic losses to the swine producers. Typical clinical
signs associated with the disease include late-term reproductive failure in pregnant sows and
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respiratory distress in young pigs [2]. Recently, a highly pathogenic form of PRRS (HP-
PRRS) has emerged in Asia, causing death in pigs of all ages with the mortality up to 100%
[3]. The etiologic agent of PRRS is an RNA virus that belongs to the family Arteriviridae,
the order Nidovirales, and is referred to as PRRS virus (PRRSV) [4–6]. The PRRSV
genome is a linear, positive sense and single stranded RNA molecule of about 15 kb in
length, which is flanked by a methyl-cap and a poly (A) tail at its 5′ and 3′ end, respectively
[7–9]. It encodes a total of 14 non-structural and 8 structural proteins [7–9], none of which
are known to be dispensable for the viral replication cycle.
Vaccines for protection against PRRSV infection have been commercially available since
1994. Two types of PRRSV vaccines are licensed for clinical applications including
inactivated and live-attenuated vaccines. No subunit PRRSV vaccines are available at the
present. It has been demonstrated that live-attenuated vaccines are much more effective than
inactivated vaccines [10,11]. Under field conditions, the use of live-attenuated PRRSV
vaccines improves pigs′ performance but co-circulation of field virus and vaccine virus has
been reported to occur in the vaccinated herds [12,13]. Under experimental conditions,
current live-attenuated vaccines protect the vaccinated pigs from development of clinical
disease but they often fail to prevent infection and shedding of the challenge viruses [11,14–
16]. One major limitation of the current live-attenuated PRRSV vaccines is that they do not
allow serological discrimination between naturally infected and vaccinated animals, a
property designated as DIVA (differentiating infected from vaccinated animals).
DIVA vaccines are vaccines that lack at least one antigenic component (so-called serologic
marker antigen) when compared to the corresponding wild-type viruses [17]. Therefore,
only wild-type virus infected, but not vaccinated, animals will develop antibodies to the
marker antigen. Consequently, serological assays that detect antibodies specific to the
marker antigen can be used to identify wild-type virus infected animals in the vaccinated
population. The use of DIVA vaccines is preferred or even mandatory in animal health
campaigns aiming toward control and eradication of important animal diseases [17–19].
Classically, live-attenuated DIVA vaccines are generated through deletion of an entire gene
encoding an immunogenic, non-essential protein [17]. While technically straightforward in
the case of some double-stranded DNA viruses like Pseudorabies Virus (Suid Herpesvirus
1), it is very difficult to delete an entire gene of a smaller RNA genome virus like PRRSV,
whose genes are all essential for the productive viral infection [20–23]. An alternative
approach to develop live-attenuated DIVA vaccines for RNA viruses is to selectively
eliminate a small protein fragment or an epitope, instead of deleting the whole protein [24–
26]. Previously, we identified several immunodominant B-cell epitopes located in non-
structural protein 2 (nsp2) and in different structural proteins of a type-II PRRSV strain
FL12 [27]. In the present study, we provide detailed characterization of a conserved and
immunodominant epitope located at the carboxyl-terminus of PRRSV M protein and
propose to use this epitope as a serologic marker for development of live-attenuated DIVA
vaccines against type-II PRRSV.
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2. Materials and methods
2.1. Antibodies and viruses
A hybridoma cell line expressing monoclonal antibody (MAb) specific to the peptide-M201
(161AVKQGVVRLVKYAK174) [27] was produced through a contract with the
Immunological Resource Center (Urbana, IL). The peptide was conjugated with Keyhole
Lipet Hemocyanin (KLH) and used to immunized mice. After the hybridoma cell line was
achieved, ascites fluid production and antibody purification and HRP-conjugation were done
through a contract with GenScript USA Inc. (Piscataway, NJ). MAb SDOW-17 specific for
PRRSV nucleocapsid protein was purchased from National Veterinary Services Laboratories
(Ames, IA). PRRSV negative and positive control serum samples were collected from
different experiments previously conducted in our laboratory [28,29]. These included sera
from 36 pigs that had been infected with PRRSV strain FL12 or its derivative mutants and
28 pigs that had been infected with PRRSV strain PRRSV-01 or its derivative mutants.
These mutant viruses carry different N-linked glycosylation sites in their GP3 and GP5 but
they all have intact M protein sequence [28,29]. The PRRSV vaccine strain Prime Pac has
been obtained from a commercial batch of that vaccine received in our laboratory in 1997
and maintained through several passages in MARC-145 cells [30]. The collection of 82
type-II PRRSV field-isolates used in this study were collected from Midwestern states (NE,
IA and IL) of the U.S.
2.2. Plasmid construction
For alanine-scanning mutagenesis, PRRSV ORF6 carrying alanine substitutions within
epitope-M201 region was prepared by site-directed mutagenesis using synthesized
mutagenic primers (Table 1). The resulting PCR products were cloned into the pIHA
plasmid [31] at the XhoI and NotI restriction enzyme sites. The megaprimer PCR method
[32] was used to prepare mutant pFL12 plasmids that contain mutations in the epitope-M201
region of the PRRSV strain FL12 [33].
2.3. Recovery and in vitro characterization of mutant viruses
Recovery of mutant viruses from the full-genome cDNA clones was done as previously
described [33,34]. Multiple step growth kinetics were performed in MARC-145 [35].
Reactivity of the mutant viruses with different MAbs was analyzed by indirect
immunofluorescent assay [30].
2.4. Blocking ELISA
Details of the bELISA protocol are described in the supplemental section.
2.5. Animal experiments
All pigs used in this research were housed and handled following the protocols approved by
the Institutional Animal Care Committee at University of Nebraska-Lincoln. The pigs were
purchased from a swine herd with certified records of absence of PRRSV infection and were
accommodated in an isolated bio-safety level-2 facility. The pigs were about 3–4 weeks of
age at the beginning of the experiment. The pigs were separately infected with one of the
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following PRRSV strains: PP-virus, Q164R and N168R. In all cases, the pigs were
inoculated intramuscularly with 105.0 TCID50 of virus diluted in 2 ml of cell culture
medium. Serum samples were collected from all animals before infection and periodically
after infection and stored in small aliquots at −80 °C for serological and virological analysis.
3. Results
3.1. Epitope-M201 is conserved and immunodominant
Epitope-M201, spanning the residues 161–174 of M protein (Fig. 1A) is well conserved
among type-II PRRSV isolates. Analysis of 100 type-II PRRSV M protein sequences
collected from GenBank revealed that all of the amino acid residues of epitope-M201 were
identical except the residue at position 164, where 16% of the analyzed sequences had a
substitution from glutamine to arginine (Fig. 1B). The monoclonal antibody specific to
epitope-M201 (MAb-201) recognized 92% (n = 82) PRRSV field-isolates originating from
the Midwestern states of the U.S. (Fig. 1C), confirming the conservation of this epitope.
Through pepscan analysis, we reported previously that 100% (n = 15) of pigs infected with
the highly virulent PRRSV strain FL12 developed antibodies against epitope-M201 [27]. To
further confirm the immunogenicity of this epitope, we developed a bELISA that allowed us
to measure antibodies to epitope-M201 more specifically. Using this bELISA we showed
that 63 out of 64 pigs (98.4%) infected pigs had antibodies specific to epitope-M201 at 35
days p.i. (Fig. 1D). Detailed analysis revealed that antibodies to epitope-M201 appeared at
about 14 days p.i. (Fig. 1E). Together, the results presented here confirm that epitope-M201
is highly immunodominant as previously anticipated [27].
3.2. Core amino acid sequence of epitope-M201
To determine the core amino acid residues of the epitope-M201, we constructed an
expression vector encoding the M protein of PRRSV strain FL12. Using this vector as a
backbone, we performed alanine-scanning mutagenesis where amino acids of the epitope-
M201 were replaced by alanine (Table 2). Cells expressing the Mut-4 construct carrying
alanine substitutions at the last 4 amino acids of epitope-M201 were still recognized by
MAb-201. By contrast, cells transfected with mutant plasmids carrying substitutions within
the first 10 amino acids were not recognized by MAb-201. The results indicated that the
core amino acid sequence of epitope-M201 resided within its first 10 amino acids (residue
161–170).
3.3. Generation and characterization of N168R mutant virus
Mutations that disrupt the antigenicity of epitope-M201, as determined by transient
expression, were incorporated into the pFL12 plasmid [33]. At 48 h post-electroporation
with the mutant RNA transcripts, cells were immunostained with MAb SDOW-17 specific
to viral N protein. Specific signal was detected from cells electroporated with all mutant
RNA transcripts (data not shown), suggesting that mutations within epitope-M201 did not
affect viral sub-genomic mRNA transcription. However, we could not recover viable mutant
viruses from any of those constructs (Table 2), indicating that amino acids within the
epitope-M201 region were essential for productive infection.
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By comparison between Mut-4 and Mut-6 constructs (Table 2), it appeared that a single
amino acid substitution from asparagine to alanine at position 168 was sufficient to abolish
the antigenicity of epitope-M201. Further analysis revealed that 5 out of 16 amino acids at
the carboxyl-terminus of the FL12 M protein, including 3 residues inside epitope-M201 and
2 residues immediately upstream of epitope-M201, were positively charged. Consequently, a
mutant virus N168R was generated by mutating asparagine 168 to arginine, a positive
charge amino acid, instead of alanine. The N168R mutant virus replicated as efficiently as
the parental wild-type FL12 in cell culture (Fig. 2A). More importantly, the N168R mutant
did not react with MAb-201 (Fig. 2B), indicating that antigenicity of epitope-M201 was
successfully disrupted.
To study the stability and immunogenicity of the N168R mutation 4 recently weaned pigs
were infected with N168R mutant virus. Analysis of the consensus sequences of the viruses
from serum samples collected at 7 days p.i. revealed that two viruses exhibited arginine to
asparagine mutation; one virus displayed arginine to serine mutation and one had an
ambiguous sequence (Fig. 2C). Detailed analysis of the sequencing chromatograms
indicated that all the serum-derived viruses carried a mix of nucleotide sequences at codon
168 (Fig. 2D). All pigs infected with N168R mutant were tested positive by the bELISA at
32 days p.i. (Fig. 2E). The results further confirmed that reversion mutation had occurred in
all 4 infected pigs. As expected, all infected pigs were tested positive by the IDEXX ELISA
(Fig. 2F).
3.4. Generation and characterization of Q164R mutant virus
To seek a more stable mutant deprived of epitope-M201 immunogenicity, we investigated
the M protein sequences of PRRSV strains/isolates that were naturally not recognized by
MAb-201 (Fig. 1C) and found that they all carried a single amino acid substitution within
the epitope-M201 region, from glutamine to arginine at position 164 (Q164R) (Fig. 3A). To
test whether the Q164R substitution was sufficient to abolish the antibody response to
epitope-M201, a group of 10 pigs were inoculated with the attenuated PRRSV vaccine strain
Prime Pac (herein designated as PP-virus) [36], one of the PRRSV strains that were not
recognized by MAb-201 (Fig. 3A). Serum samples collected from pigs infected with PP-
virus were tested negative by the bELISA (Fig. 3B), indicating that the Q164R substitution
eliminates the immunogenicity of epitope-M201.
Based on this finding, we constructed the Q164R mutant virus by mutating glutamine 164 to
arginine. In addition, we also incorporated into the Q164R mutant virus two additional
mutations (arginine 159 to lysine and lysine 160 to arginine) that are located immediately
upstream of epitope-M201. We reasoned that the incorporation of these two additional
mutations may help stabilize the Q164R mutation because they were commonly found in the
epitope-M201 negative PRRSV isolates (Fig. 3A). The growth kinetics of Q164R mutant
virus was slightly reduced as compared to the wild-type FL12 strain (Fig. 4A). Importantly,
the Q164R mutant virus was no longer recognized by MAb-201 (Fig. 4B), indicating that
antigenicity of epitope-M201 was successfully disrupted.
Two pigs were inoculated with Q164R mutant virus to study the stability and
immunogenicity of the virus. ORF6 region of the virus in serum samples collected at 14
Vu et al. Page 5
Vaccine. Author manuscript; available in PMC 2014 September 02.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
days p.i. was sequenced, which confirmed that all 3 mutations of the Q164R mutant virus
were stably maintained at this time point (Fig. 4C and D). As expected, antibodies to
epitope-M201 were absent in pigs infected with the Q164R mutant virus at all time-points
analyzed (Fig. 4E). Conversely, all infected pigs were tested positive by the IDEXX ELISA
(Fig. 4F). Together, the results confirm that that the Q164R mutation eliminates the
immunogenicity of epitope-M201.
4. Discussion
Since the initial application of DIVA vaccines to eradicate Pseudorabies Virus in pigs,
epidemiological and regulatory considerations dictate that a DIVA vaccine should be
designed based on a “negative” serologic marker antigen [17,19]. A serologic marker
antigen is a viral protein or an epitope that is absent (thus “negative”) from the vaccine
strains but consistently present in the corresponding wild-type viruses. Therefore, only
animals that have been infected with wild-type virus will develop antibodies against the
serologic marker antigen while the vaccinated animals will not. The most critical step in the
development of a live-attenuated DIVA vaccine is the identification of a potential serologic
marker antigen. Since a DIVA vaccine is only useful if it is used in conjunction with a
companion diagnostic test, the marker antigen should be conserved and immunodominant to
ensure that the companion diagnostic test based on this marker antigen will produce reliable
diagnostic results. In addition, the marker antigen should be dispensable for the viral life
cycle but should not contribute significantly to the overall immunogenicity of the vaccine.
These two criteria are to ensure that elimination of the marker antigen from the viral genome
will not adversely affect the viral replication and its ability to elicit protective immunity. The
PRRSV genome encodes 14 non-structural and 8 structural proteins, several of which are
well conserved and/or highly immunogenic [37–40]. Up to now, efforts to delete an entire
gene of PRRSV have not been successful [20–23]. Therefore, the most feasible approach to
develop a live-attenuated DIVA vaccine against PRRSV would be selectively eliminating a
small protein fragment or an epitope, instead of deleting an entire protein. Thus far, efforts
to develop a DIVA vaccine for PRRSV have been focused on deleting different
immunogenic fragments of the viral nsp2 because this protein can tolerate large deletions
[41–43]. However, the biggest shortcoming of the nsp2-mutant viruses, in the context of a
DIVA vaccine, is that the differential peptide-based ELISA used in conjunction with the
DIVA vaccine has very limited diagnostic sensitivity [42], mainly due to the substantial
genetic variation of the nsp2 [44,45].
Epitope-M201 can be a potential serologic marker candidate for development of a live-
attenuated DIVA vaccine against PRRSV. The epitope is highly immunodominant and well-
conserved among PRRSV isolates. In addition, the epitope does not seem to contribute
significantly to the protective immunity against PRRSV infection because a polyclonal
antibody specific to this epitope, as well as MAb-201, lacks PRRSV-neutralizing ability
(unpublished results). Initially, we attempted to delete the whole or portions of epitope-
M201 because this would minimize the chance of reversion to wild-type sequence.
Unfortunately, we could not recover any mutant viruses carrying deletions in the epitope-
M201 region (unpublished results). Similarly, we could not recover any viruses that carried
multiple amino acid substitutions within epitope-M201 (Table 2). The results indicate the
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important functions of this protein segment in the viral replication cycle. Epitope-M201 is
located at the cytoplasmic tail of M protein, which has been suggested to interact with N
protein [46]. It is possible that deletions or substitutions of multiple amino acids within
epitope-M201 may interfere with the interaction between M and N proteins, thus, being
detrimental to the virus. Through studying PRRSV isolates that were naturally not
recognized by MAb-201, we identified that a single amino acid substitution Q164R is
sufficient to abolish the immunogenicity of epitope-M201. We demonstrated that the Q164R
mutation can be introduced into the genome of the PRRSV strain FL12 without severely
impairing the viral replication. Importantly, the Q164R mutant virus stably maintained its
mutations and lost its capacity to elicit antibodies to epitope-M210 when it was inoculated
into pigs. It has been previously reported that reversion to wild-type sequence occurred after
the PRRSV mutant viruses were inoculated into pigs [47]. In the present study, we observed
that the N168R mutant virus, but not the Q164R mutant virus, quickly reverted to wild-type
sequence after the first week of inoculation into the pigs. We believe that the Q164R mutant
virus was stable in vivo because it carries mutations mimicking the natural PRRSV
sequences that have already been selected by nature.
Validation data based on a set of control serum samples collected from pigs experimentally
infected with different PRRSV strains indicated that our bELISA could correctly detect
98.4% (n = 64) infected animals (Fig. 1D). However, before the definitive adoption of this
bELISA as a companion serological test to be used with the epitope-M201-negative DIVA
vaccine, it would be essential to validate the performance of this test with a large collection
of clinical serum samples. Our results indicate that eitope-M201 is absent in approximately
10–15% of PRRSV field isolates (Fig. 1B and C). This will potentially affect the diagnostic
sensitivity of our bELISA. In the scenario that our bELISA has significantly low diagnostic
sensitivity when it is used with clinical serum samples, the test may need to be used for herd
diagnosis instead of individual animal diagnosis. This way, the low diagnostic sensitivity of
the test may be overcome by increasing the test samples collected from each herds.
Alternatively, we could consider the possibility of eliminating one additional marker epitope
from the genome of the Q164R mutant virus to produce a double negative marker PRRSV
strain that simultaneously lacks 2 immunodominant epitopes in its genome. This is based on
the contention that the occurrence of PRRSV field strains that simultaneously lack two
immunodominant marker epitopes would be negligible.
In summary, we report here the characterization of a potential serological marker epitope
located in the M protein of PRRSV. We demonstrate that the immunogenicity of this epitope
can be eliminated through the introduction of a single amino acid mutation which does not
severely affect the viral replication. We believe that this mutation can be easily introduced
into the genome of conventional live-attenuated type-II PRRSV vaccine strains in order to
convert them into vaccine with DIVA capability.
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Fig. 1.
Epitope-M201 is highly conserved and immunodominant. (A) Prediction of transmembrane
helixes and topology of the PRRSV strain FL12 M protein. The figure was generated
through the use of the web based application SOSUI engine ver. 1.11. Epitope-M201 is
outlined in red at the carboxyl-terminus of the protein. (B) Sequence logo of epitope-M201
generated from 100 type-II PRRSV M protein sequences collected from GenBank. The
relative positions of the amino acids are indicated in the X-axis. The height of symbols
within the stack indicates the relative frequency of each amino at that position. The figure
was generated through the use of the web based application WebLogo 3.3. (C) Reactivity of
MAb-201 with 82 type-II PRRSV strains/isolates as determined by indirect
immunofluorescence assay (IFA). (D) Validation of the bELISA. The positive and negative
control sera were collected from 64 pigs before infection and at 35 days p.i. (details of the
serum samples are described in Section 2). (E) Kinetics of seroconversion to epitope-M201
as determined by bELISA. The sera were collected from the same pigs mentioned in panel
(D). The horizontal dotted line represents the cut-off of the assay. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of the
article.)
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Fig. 2.
Characterization of the N168R mutant virus. (A) Multiple step growth curves of the
indicated viruses upon infection of MARC-145 cells. Viral titers are expressed as mean and
standard error of mean (SEM) of data obtained from three independent experiments. (B)
Reactivity of the indicated virus with different MAbs. (C) ORF6 region of viruses in the
serum samples collected at 7 days p.i. was amplified by RT-PCR and subjected to DNA
sequencing. The consensus sequences of the serum-derived viruses were aligned with that of
input virus (before inoculation). Only the epitope-M201 region is shown. The conserved
residues in the aligned sequences are indicated by (.). The X represents the ambiguous
sequence. (D) Sequencing chromatograms of one representative serum-derived virus (from
pig # 918) at 7 days p.i. Only region covering the mutation sites is shown. The triplet codon
168 is underlined. (E) Seroconversion to epitope-M201 of pigs infected with N168R mutant
virus as measured by bELISA. Data are expressed as mean and SEM of 4 infected pigs. For
the comparison purposes, kinetics of seroconversion to epitope-M201 of pigs infected with
FL12 and PRRSV-01 (Fig. 1E) are shown. (F) Antibodies to N protein of pigs infected with
N168R mutant virus as determined by the IDEXX ELISA. Data are expressed as mean and
SEM of 4 infected pigs. The horizontal dotted lines in panels (E) and (F) indicate the cut-off
of the assays.
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Fig. 3.
A single amino acid substitution Q164R is sufficient to disrupt epitope-M201. (A) Multiple
sequence alignment of the epitope-M201 region of the PRRSV isolates that were naturally
not recognized by MAb-201. Conserved residues in the aligned sequences are indicated by
(.). The gray box depicts epitope-M201 region. (B) Seroconversion to epitope-M201 of pigs
infected with the attenuated PRRSV vaccine strain Prime Pac (PP-virus) as measured by
bELISA. Data are expressed as mean and SEM of 10 infected pigs. Kinetics of
seroconversion to epitope-M201 of pigs infected with FL12 and PRRSV-01 (Fig. 1E) are
shown for the comparison purposes. The horizontal dotted line indicates the cut-off of the
assay.
Vu et al. Page 13
Vaccine. Author manuscript; available in PMC 2014 September 02.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Characterization of the Q164R mutant virus. The experiments in this figure were done
similar to those described in Fig. 3. (A) Multiple step growth curves. (B) Reactivity with
different MAbs. (C) Multiple sequence alignment of the epitope-M201 regions of the viruses
from serum samples collected at 14 days p.i. (D) Sequencing chromatograms of one
representative serum-derived virus (from pig #860) at 14 days p.i. The triplet codons where
amino acid mutations were introduced are underlined. (E) Seroconversion to epitope-M201
of pigs infected with Q164R mutant virus measured by bELISA. (F) Antibodies to N protein
of pigs infected with Q164R mutant virus as determined by the commercial IDEXX ELISA.
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Table 1
Primers used in this study
Primers Nucleotide sequence (5′ → 3′)
For construction of pIHA plasmids encoding wild-type or mutant ORF6
 ORF6For ATATATCTCGAGGGGTCGTCTTTAGACGACTTTTG
 ORF6Rev ATATATGCGGCCGCTTATTTGGCATATTTGACAAG
 Mut-1Rev ATATATGCGGCCGCTTATTTGGCATATTTGACAAGGTTTACCACTCCTGCTGCTGCAGCTTTTCTGCCA
 Mut-2Rev ATATATGCGGCCGCTTATTTGGCATATTTGACAAGGTTTGCTGCTGCCTGTTTAACAGCTTTTC
 Mut-3Rev ATATATGCGGCCGCTTATTTGGCATATTTGGCAGCGGCTACCACTCCCTGTTTAAC
 Mut-4Rev ATATATGCGGCCGCTTAAGCGGCAGCAGCGACAAGGTTTACCACTCC
 Mut-5Rev ATATATGCGGCCGCTTATTTGGCATATTTGACAAGGTTTACCACTCCCGCAGCAACAGCTTTTCTGCC
 Mut-6Rev ATATATGCGGCCGCTTAGGCGGCATAGGCGACAAGGGCTACCACTCCCTGTTTAAC
For construction of full-length pFL12 plasmids containing different mutations in epitope-M201
 Mut-1For TGGCAGAAAAGCTGCAGCAGCAGGAGTGGTAAACCTTG
 Mut-2For GAAAAGCTGTTAAACAGGCAGCAGCAAACCTTGTCAAATATG
 Mut-3For AAAGCTGTTAAACAGGGAGTGGTAGCCGCTGCCAAATATGCCAAATAACAAC
 Mut-5For GTTGGGTGGCAGAAAAGCTGTTGCTGCTGGAGTGGTAAACCTTG
 Mut-6For CAGGGAGTGGTAGCCCTTGTCGCCTATGCCGCCTAACAACGGCAAGCAGCA
 N168RFor CAGGGAGTGGTAAGGCTTGTCAAATATGCC
 Q164RFor GTGTTGGGTGGCAAGCGCGCTGTTAAAAGAGGAGTGGTAAAC
 11691For GCAACAGAAGAGTTGTCGGGTCC
 A70Rev CACACTTAATTAACGT(70)AATTTCGGCCGCATG
Mutated nucleotides are underlined. Restriction enzyme sites incorporated into the primers for cloning purposes are shown in bold.
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Table 2
Mutagenesis to disrupt the antigenicity of epitope-M201
Constructs Sequence IFAa Virus recovery
Wil d type 161AVKQGVVNLVKYAK174 +++ +++
Mut-1 .AAA.......... - -
Mut-2 ....AAA....... - -
Mut-3 .......AAA.... - -
Mut-4 ..........AAAA +++ NDb
Mut-5 ..AA.......... - -
Mut-6 .......A..A..A - -
a
IFA: indirect immunofluorescence assay with the MAb-201.
bND, not done.
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